Although Ras/MAPK activating mutations are rare in breast cancer (5), they can occur infrequently (19), and we and others have previously reported loss of Ras/MAPK negative regulators (DUSP4, NF1, RND1) in breast cancer as a mechanism of pathway activation (6, 7, 20, 21). This evidence concerns the gene RND1 and breast carcinoma.